Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile

Clinical Endocrinology

Volumn 73, Issue 6, 2010, Pages 769-776

  Rasmussen, Michael Højby ^a   Jensen, Lene ^a   Anderson, Thomas W ^a   Klitgaard, Thomas ^a   Madsen, Jesper ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; NNC 1260083; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GROWTH HORMONE DEFICIENCY; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; JAPANESE; LIPOATROPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 78649237780     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03863.x     Document Type: Article

References (27)

1. Richmond, E.J., &, Rogol, A.D., (2008) Growth hormone deficiency in children. Pituitary, 11, 115 - 120.
2. Molitch, M.E., Clemmons, D.R., Malozowski, S., et al. (2006) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 91, 1621 - 1634.
3. Ho, K.K., (2007) GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology, 157, 695 - 700.
4. Smith, S.L., Hindmarsh, P.C., &, Brook, C.G.D., (1993) Compliance with growth hormone treatment - are they getting it? Archives of Disease in Childhood, 68, 91 - 93.
5. Desrosiers, P., O'Brien, F., &, Bletchen, S., (2005) Patient outcomes in the GH-Monitor: the effect of delivery device on compliance and growth. Pediatric Endocrinology Reviews, 2 (Suppl. 3), 327 - 331.
6. Kapoor, R.R., Burke, S.A., Sparrow, S.E., et al. (2008) Monitoring of concordance in growth hormone therapy. Archives of Disease in childhood, 93, 147 - 148.
7. Rosenfeld, R.G., &, Bakker, B., (2008) Compliance and persistence in paediatric and adult patients receiving growth hormone therapy. Endocrine Practice, 14, 143 - 154.
8. Ranke, M.B., Lindberg, A., Albertsson-Wikland, K., et al. (2005) Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS. Journal of Clinical Endocrinology and Metabolism, 90, 1966 - 1971.
9. Attanasio, A.F., Howell, S., Bates, P.C., et al. (2002) Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood. Clinical Endocrinology, 56, 503 - 507.
10. Gibney, J., Wallace, J.D., Spinks, T., et al. (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 84, 2596 - 2602.
11. Giavoli, C., Cappiello, V., Porretti, S., et al. (2003) Growth hormone therapy in GH-deficient adults: continuous vs alternate-days treatment. Hormone and Metabolic Research, 35, 557 - 561.
12. Laursen, T., Gravholt, C.H., Heickendorff, L., et al. (2001) Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 86, 1222 - 1228.
13. Reiter, E.O., Attie, K.M., Moshang Jr, T., et al. (2001) Genentech, Inc.-Alkermes, Inc. Collaborative Study Group. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism, 86, 4700 - 4706.
14. Cook, D.M., Biller, B.M., Vance, M.L., et al. (2002) The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 87, 4508 - 4514.
15. Hoffman, A.R., Biller, B.M., Cook, D., et al. (2005) Genentech Adult Growth Hormone Deficiency Study Group. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. Journal of Clinical Endocrinology and Metabolism, 90, 6431 - 6440.
16. Bidlingmaier, M., Kim, J., Savoy, C., et al. (2006) Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism, 91, 2926 - 2930.
17. Harris, P.E., Didier, E., Kantaridis, C., et al. (2006) First in human study of pegylated recombinant growth hormone. Hormone Research, 65 (Suppl. 4), 30.
18. Abs, R., Didier, E., Boonen, A., et al. (2006) The pharmacokinetics, pharmacodynamics and safety of pegylated recombinant human growth hormone after single subcutaneous injections in adult male patients with growth hormone deficiency. Hormone Research, 65 (Suppl. 4), 148.
19. Touraine, P., D'Souza, G.A., Kourides, I., et al. (2009) GH Lipoatrophy Study Group. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. European Journal of Endocrinology, 161, 533 - 540.
20. Veronese, F.M., Mammucari, C., Schiavon, F., et al. (2001) Pegylated enzyme entrapped in poly(vinyl alcohol) hydrogel for biocatalytic application. Farmaco, 56, 541 - 547 PubMed PMID: 11601638.
21. Harris, J.M., Martin, N.E., &, Modi, M., (2001) Pegylation: a novel process for modifying pharmacokinetics. Clinical Pharmacokinetics, 40, 539 - 551.
22. Hamidi, M., Azadi, A., &, Rafiei, P., (2006) Pharmacokinetic consequences of pegylation. Drug Delivery, 13, 399 - 409.
23. Rasmussen, M.H., Bysted, B., Anderson, T.W., et al. (2010) Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. Journal of Clinical Endocrinology and Metabolism, 95, 3411 - 3417.
24. Porter, J.H., Edwards, G.A., &, Charman, S.A., (2001) Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Advanced Drug Delivery Reviews, 50, 157 - 171.
25. Amato, G., Mazziotti, G., Di Somma, C., et al. (2000) Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. Journal of Clinical Endocrinology and Metabolism, 85, 3720 - 3725.
26. Kemp, S.F., Fielder, P.J., Attie, K.M., et al. (2004) Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. Journal of Clinical Endocrinology and Metabolism, 89, 3234 - 3240.
27. Webster, R., Xie, R., Didier, E., et al. (2008) PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica, 38, 1340 - 1351.